RNA NASDAQ
Atrium Therapeutics, Inc.
1W: -1.7%
1M: -4.5%
3M: -82.1%
YTD: -81.9%
1Y: -56.9%
3Y: +15.9%
5Y: -33.5%
$13.09
+0.05 (+0.38%)
Weekly Expected Move ±5.8%
$12
$12
$13
$14
$15
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$223.9M
52W Range11.95-16.77
Volume291,689
Avg Volume732,632
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOKathleen Gallagher
Employees511
SectorHealthcare
IndustryBiotechnology
IPO Date2026-02-27
Websiteatriumtherapeutics.com
10578 Science Center Drive
San Diego, CA 92121
US
San Diego, CA 92121
US
619 876 0700
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Latest News
Avidity Biosciences, Inc. $RNA Shares Sold by Assetmark Inc.
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Capricorn Fund Managers Ltd Buys 57,663 Shares of Avidity Biosciences, Inc. $RNA
FNY Investment Advisers LLC Buys 43,380 Shares of Avidity Biosciences, Inc. $RNA
Recent Insider Trades
No insider trades found